Inhibrx Biosciences, Inc. INBX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $161.66M-25.3% | $124.22M-18.6% | $153.09M-22.0% | $186.57M-17.8% | $216.52M-14.2% | ||
| $171.34M-23.3% | $132.83M-17.2% | $161.42M-22.2% | $193.96M-19.9% | $223.39M— | ||
| $3.2M-42.4% | $3.73M-39.8% | $4.31M-37.4% | $4.89M-35.8% | $5.55M— | ||
| $183.97M-24.2% | $146.48M-19.0% | $177.47M-20.3% | $212.12M-17.9% | $242.64M— | ||
| $8.76M-1.5% | $5.94M-35.7% | $6.77M-45.2% | $8.29M-36.3% | $8.89M+120% | ||
| $26.51M-39.2% | $33.8M-17.0% | $35.98M-18.4% | $38.94M-0.3% | $43.64M— | ||
| $174.99M+77.4% | $100.56M— | $99.92M— | $99.28M— | $98.65M— | ||
| $205M+38.3% | $138.49M+194% | $140.64M+219% | $143.56M+268% | $148.2M— | ||
| 120M0.0% | 120M+11,999,900% | 120M0.0% | 120M0.0% | 120M— | ||
| -$279.63M-87.1% | -$246.19M-132% | -$213.35M-266% | -$178.1M-1,137% | -$149.44M— | ||
| -$21.04M-122% | $7.99M-94.0% | $36.83M-79.4% | $68.56M-68.7% | $94.44M+716% | ||
| $183.97M-24.2% | $146.48M-19.0% | $177.47M-20.3% | $212.12M-17.9% | $242.64M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Inhibrx Biosciences, Inc.'s total assets?
- Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
- How much debt does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
- How much cash does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
- Can Inhibrx Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 6.46 — current assets exceed current liabilities.
- Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.